Latest Asx Market News

ASIC has initiated a comprehensive compliance inquiry into ASX’s governance, risk management, and operational capabilities, folding its previous CHESS incident probe into this broader review. ASX pledges full cooperation amid ongoing technology upgrades.

Hawsons Iron Ltd has been reinstated to ASX trading following an announcement of a proposed capital raising, signaling renewed investor interest.

VanEck Investments Limited has released a replacement Product Disclosure Statement for its VanEck Bentham Global Capital Securities Active ETF (ASX, GCAP), outlining an actively managed strategy focused on global subordinated debt securities with income and diversification benefits.

Ridley Corporation has successfully closed its retail entitlement offer, raising $26 million as part of a $125 million capital raise to fund its $300 million acquisition of Incitec Pivot’s fertiliser distribution business.

Victor Group Holdings has requested a voluntary suspension of its shares starting June 2, pending a significant acquisition announcement expected by June 5.

Fintech Chain Limited has applied to delist from the ASX, citing low valuation, poor liquidity, and high costs, aiming to unlock growth capital in China and the US.

The Takeovers Panel has declined to investigate applications challenging Pact Group Holdings’ proposed delisting, signaling regulatory acceptance of the move. The decision clarifies the Panel’s jurisdiction and leaves the delisting process on track.

Mayne Pharma has clarified why it did not disclose an FDA Untitled Letter to the market despite sharing it with its scheme bidder, reaffirming compliance with ASX rules amid recent share price volatility.

Island Pharmaceuticals has raised $3.6 million through a strategic share placement to advance its lead antiviral drug ISLA-101’s clinical development and broaden its asset portfolio ahead of pivotal Phase 2a/b trial results.

Tivan Limited’s shares have been suspended at the company’s request pending a major joint venture announcement and its response to an ASX compliance query.

Dimerix has received a US$30 million upfront payment from Amicus Therapeutics for exclusive US rights to DMX-200, a promising kidney disease therapy. The deal positions Dimerix for up to US$560 million in further milestones plus royalties, underpinning its global licensing strategy.

Enlitic Inc. has been reinstated to trading on the ASX following its announcement of a new equity raise, signaling renewed investor interest in the health technology firm.